Mitochondrial Priming Determines Senolytic Resistance via G1/G2 Cell Cycle–Dependent Metabolic Rewiring
Hypothesis
Senolytic resistance arises because senescent cells arrested in G1 versus G2 adopt distinct mitochondrial configurations that dictate their susceptibility to stress‑induced death; G1‑arrested senescent cells rely on fatty‑acid oxidation (FAO) and resist mitophagy, whereas G2‑arrested senescent cells depend on glycolysis and are primed for mitochondrial permeabilization.
Mechanistic Rationale
Recent work links senolytic efficacy to mitochondrial stress induction [3]. Cell‑cycle position shapes metabolic programming: G1 arrest correlates with elevated CPT1A expression and increased reliance on mitochondrial FAO for ATP production [2]. This FAO‑dependent state sustains high NAD+/NADH ratios, stabilizing SIRT3 activity and suppressing ROS‑mediated permeability transition pore opening. In contrast, G2 arrest shows upregulation of HK2 and LDHA, shifting ATP generation to cytosolic glycolysis and lowering mitochondrial membrane potential, which sensitizes cells to BCL‑2 family inhibition (e.g., navitoclax) and ROS‑triggered mPTP opening.
We propose that resistant senescent cells are predominantly G1‑arrested, FAO‑dependent, and can be "sensitized" by pharmacologically forcing a metabolic shift toward glycolysis (e.g., with etomoxir to inhibit CPT1A or dichloroacetate to activate pyruvate dehydrogenase). This shift would collapse the NAD+ buffer, increase mitochondrial ROS, and lower the threshold for senolytic‑induced mitochondrial permeabilization, thereby converting resistant cells into a senolytically sensitive state.
Testable Predictions
- Metabolic profiling: Single‑cell Seahorse analysis of senescent fibroblasts treated with DQ will reveal a subpopulation with high OCR/ECAR ratio (FAO‑high) that survives treatment; this subpopulation will show G1 markers (p21^high, cyclin D1^low) and low γH2AX.
- Sensitization experiment: Pre‑treatment with etomoxir (CPT1A inhibitor) for 6 h before DQ will increase senolytic clearance from ~45 % to >80 % in vitro, accompanied by a shift in cell‑cycle distribution toward G2/M (creased phospho‑histone H3).
- In vivo validation: In aged mice, a two‑regimen protocol (etomoxir 10 mg/kg i.p. 24 h prior to monthly DQ) will reduce p16^Ink4a^positive cells in liver and adipose tissue by >70 % compared with DQ alone, without exacerbating systemic inflammation (serum IL‑6, CRP unchanged).
- Biomarker correlation: Circulating acylcarnitine species (C16:0, C18:1) will inversely correlate with senolytic responsiveness across human subjects; elevated levels predict resistance and will normalize after etomoxir priming.
Implications
If validated, this hypothesis reframes resistance not as a static property but as a metabolically gated state that can be therapeutically overridden. It suggests optimizing senolytic schedules by inserting a brief metabolic priming window, potentially lowering required drug doses and mitigating off‑target toxicity. Furthermore, it provides a mechanistic basis for integrating metabolic inhibitors into existing senolytic trials, addressing the current bottleneck of heterogeneous responses and the "ticking time bomb" resistant population.